MedTrace Logo

SGLT2i in Diabetic Patients with Renal Transplantation

NCT06731231 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-12-12

No results posted yet for this study

Summary

Post-transplant diabetes mellitus (PTDM), previously known as New Onset Diabetes After Transplantation defined as the diagnosis of diabetes mellitus (DM) in a previously non-diagnosed diabetic person after transplantation. PTDM is a common and serious post-transplant complication that threatens graft survival, increases incidence of infection and development of cardiovascular complications

The primary objective of this study is to assess efficacy and safety of dapagliflozin in patients with post-transplantation diabetic patients

Conditions

  • Post-transplant Diabetes Mellitus

Interventions

DRUG

SGLT2 inhibitor

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are glucose lowering agents used in the treatment of type 2 DM by improving glycemic control, weight reduction, blood pressure control and albuminuria. the use of SGLT2i as a cardiorenal protective tool may be of particular value in renal transplant patients due to the risk of multiple comorbidities such as diabetes and hypertension. Recently, sodium-glucose transport protein 2 inhibitors (SGLT2i) emerged as a new class of therapeutics with beneficial effects on both cardiovascular (CV) and kidney outcomes in patients with diabetic kidney disease, nondiabetic proteinuric chronic kidney disease (CKD), and heart failure with and without diabetes in patients with native kidneys

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2024-12-15
Completion
2025-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06731231 on ClinicalTrials.gov